Celgene (NASDAQ: CELG)has certainly had its challenges over the last year, but you wouldn't have known it from the company's first-quarter results. The big biotech announced on Friday that its Q1 revenue jumped 20% year over year, with adjusted diluted earnings per share soaring 23%.
5 Key Things You Need to Know From Celgene's Q1 Earnings Update
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться